Enhancing the proliferative and anti-tumor capabilities of effector T cells can be accomplished by targeting the elevated expression of LAG3 on CD8+ and CD4+ T cells in the bone marrow and blood of patients with multiple myeloma (144). The gene discussed is CD8A; the disease is neoplasm.